The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Current and emerging drugs for the treatment of inflammatory bowel disease
Open accessAbstract
During the last decade a large number of biological agents against tumor necrosis factor-α (TNF-α), as well as many biochemical substances and molecules specifically for the medical treatment of patients with inflammatory bowel disease (IBD), have been developed. This enormous progress was a consequence of the significant advances in biotechnology along with the increased knowledge of the underlying pathophysiological mechanisms involved in the pathogenesis of IBD. However, conventional therapies remain the cornerstone of treatment for most patients. During recent years conventional and biologic IBD therapies have been optimized. Newer mesalazine formulations with a reduced pill size and only one dose per day demonstrate similar efficacy to older formulations. New corticosteroids retain the efficacy of older corticosteroids while exhibiting a higher safety profile. The role of antibiotics and probiotics has been further clarified. Significant progress in understanding thiopurine metabolism has improved the effective dose along with adjunctive therapies. Quite a large number of substances and therapies, including biologic agents other than TNF-α inhibitors, unfractionated or low-molecular-weight heparin, omega-3 polyunsaturated fatty acids, microbes and microbial products, leukocytapheresis, and other substances under investigation, could offer important benefits to our patients. In this paper we review the established and emerging therapeutic strategies in patients with Crohn's disease and ulcerative colitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J. F., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A., Rachmilewitz, D., Lichtiger, S., D'Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,143
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Hanauer, S. B., Sandborn, W. J., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D., Panaccione, R., Wolf, D., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,715
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P. J., Rutgeerts, P., Mason, D., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,143
Rembacken, B., Snelling, A., Hawkey, P., Chalmers, D., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,101
Järnerot, G., Hertervig, E., Friis-Liby, I., Blomquist, L., Karlén, P., Grännö, C., Vilien, M., Ström, M., Danielsson, Å., Verbaan, H., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.003 · Cited by 1,089
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,043
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Sandborn, W. J., Hanauer, S. B., Rutgeerts, P., Fedorak, R. N., Lukas, M., MacIntosh, D. G., Panaccione, R., Wolf, D., Kent, J. D., Bittle, B., et al. (2007) · Gut · doi:10.1136/gut.2006.106781 · Cited by 1,039
Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J.-F., Panaccione, R., D'Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 965
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Reinisch, W., Sandborn, W. J., Hommes, D. W., D'Haens, G., Hanauer, S., Schreiber, S., Panaccione, R., Fedorak, R. N., Tighe, M. B., Huang, B., et al. (2011) · Gut · doi:10.1136/gut.2010.221127 · Cited by 892
Beaugerie, L., Seksik, P., Nion–Larmurier, I., Gendre, J., & Cosnes, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.019 · Cited by 860
Trichuris suis therapy in Crohn’s disease
Summers, R. W., Elliott, D. E., Urban, J. F., Thompson, R., & Weinstock, J. V. (2005) · Gut · doi:10.1136/gut.2004.041749 · Cited by 762
Sandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.014 · Cited by 753
Rutgeerts, P., Hiele, M., Geboes, K., Peeters, M., Penninckx, F., Aerts, R., & Kerremans, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90121-3 · Cited by 743
Treatment of Ulcerative Colitis with a Humanized Antibody to the α 4 β 7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Dubé, R., Cohen, A., Steinhart, A. H., Landau, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042982 · Cited by 692
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Targan, S. R., Feagan, B. G., Fedorak, R. N., Lashner, B. A., Panaccione, R., Present, D. H., Spehlmann, M. E., Rutgeerts, P. J., Tulassay, Z., Volfova, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.024 · Cited by 614
Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial
Summers, R. W., Elliott, D. E., Urban, J. F., Thompson, R. A., & Weinstock, J. V. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.005 · Cited by 613
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub3 · Cited by 604
Schreiber, S., Rutgeerts, P., Fedorak, R. N., Khaliq–Kareemi, M., Kamm, M. A., Boivin, M., Bernstein, C. N., Staun, M., Thomsen, O. Ø., & Innes, A. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.064 · Cited by 580
Peyrin–Biroulet, L., Deltenre, P., de Suray, N., Branche, J., Sandborn, W. J., & Colombel, J. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.014 · Cited by 577
INTENSIVE INTRAVENOUS REGIMEN FOR SEVERE ATTACKS OF ULCERATIVE COLITIS
Truelove, S. C., & Jewell, D. P. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90552-2 · Cited by 549
Double blind, placebo controlled trial of metronidazole in Crohn's disease.
Sutherland, L., Singleton, J., Sessions, J., Hanauer, S., Krawitt, E., Rankin, G., Summers, R., Mekhjian, H., Greenberger, N., & Kelly, M. (1991) · Gut · doi:10.1136/gut.32.9.1071 · Cited by 528
Infliximab for the treatment of fistulas in patients with Crohn's disease
Ricart, E., & Sandborn, W. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70414-2 · Cited by 519
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489 · cited 1×
“81 Rembacken et al investigated whether the administration of a non-pathogenic strain of EcN was as effective as mesalazine in preventing relapse of UC as well as whether the addition of E. coli to standard medical therapy increased the rate of remission of active UC.”
Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab
Sandborn, W. J., Rutgeerts, P., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Lu, J., Horgan, K., Rachmilewitz, D., Hanauer, S. B., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.061 · Cited by 473
Triantafillidis, J. K., Nasioulas, G., & Kosmidis, P. (2009) · PubMed · Cited by 425
Self-citationRutgeerts, P., van Assche, G., Vermeire, S., D’Haens, G., Baert, F., Noman, M., Aerden, I., de Hertogh, G., Geboes, K., Hiele, M., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.01.010 · Cited by 418
Update on glucocorticoid action and resistance
Ito, K., Chung, K. F., & Adcock, I. M. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.01.032 · Cited by 397
Feagan, B. G., Panaccione, R., Sandborn, W. J., D'Haens, G. R., Schreiber, S., Rutgeerts, P. J., Loftus, E. V., Lomax, K. G., Yu, A. P., Wu, E. Q., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.069 · Cited by 374
Adalimumab for the treatment of fistulas in patients with Crohn’s disease
Colombel, J.-F., Schwartz, D. A., Sandborn, W. J., Kamm, M. A., D’Haens, G., Rutgeerts, P., Enns, R., Panaccione, R., Schreiber, S., Li, J., et al. (2009) · Gut · doi:10.1136/gut.2008.159251 · Cited by 365
Selby, W., Pavli, P., Crotty, B., Florin, T., Radford-Smith, G., Gibson, P., Mitchell, B., Connell, W., Read, R., Merrett, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.031 · Cited by 362
Ursing, B., Alm, T., Bárány, F., Bergelin, I., Ganrot-Norlin, K., Hoevels, J., Huitfeldt, B., Jarnerot, G., Krause, U., Krook, A., et al. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80189-3 · Cited by 352
Prantera, C., Zannoni, F., Scribano, M. L., Berto, E., Andreoli, A., Kohn, A., & Luzi, C. (1996) · PubMed · Cited by 309
D'Haens, G. R., Vermeire, S., Van Assche, G., Noman, M., Aerden, I., Van Olmen, G., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.010 · Cited by 301
Oren, R., Arber, N., Odes, S., Moshkowitz, M., Keter, D., Pomeranz, I., Ron, Y., Reisfeld, I., Broide, E., Lavy, A., et al. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613046 · Cited by 297
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Chapman, R. W., Selby, W. S., & Jewell, D. P. (1986) · Gut · doi:10.1136/gut.27.10.1210 · Cited by 284
Thia, K. T., Mahadevan, U., Feagan, B. G., Wong, C., Cockeram, A., Bitton, A., Bernstein, C. N., & Sandborn, W. J. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20608 · Cited by 278
Feagan, B. G., Sandborn, W. J., Mittmann, U., Bar-Meir, S., D’Haens, G., Bradette, M., Cohen, A., Dallaire, C., Ponich, T. P., McDonald, J. W. D., et al. (2008) · JAMA · doi:10.1001/jama.299.14.1690 · Cited by 275
Adverse effects of biologics used for treating IBD
Stallmach, A., Hagel, S., & Bruns, T. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.01.002 · Cited by 266
Lichtenstein, G. R., Yan, S., Bala, M., & Hanauer, S. (2004) · American Journal of Gastroenterology · doi:10.1046/j.1572-0241.2003.04010.x · Cited by 265
Colombel, J. (1999) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(98)00816-8 · Cited by 254
Singh, S., Stroud, A. M., Holubar, S. D., Sandborn, W. J., & Pardi, D. S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001176.pub3 · Cited by 251
Helminths and the IBD hygiene hypothesis
Weinstock, J. V., & Elliott, D. E. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20633 · Cited by 243
Aminosalicylates for induction of remission or response in Crohn's disease
Lim, W.-C., Wang, Y., MacDonald, J. K., & Hanauer, S. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008870.pub2 · Cited by 239
Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial
Lewis, J. D., Lichtenstein, G. R., Deren, J. J., Sands, B. E., Hanauer, S. B., Katz, J. A., Lashner, B., Present, D. H., Chuai, S., Ellenberg, J. H., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.012 · Cited by 229
Reinisch, W., de Villiers, W., Bene, L., Simon, L., Rácz, I., Katz, S., Altorjay, I., Feagan, B., Riff, D., Bernstein, C. N., et al. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21038 · Cited by 220
Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial
Steinhart, A. H., Feagan, B. G., Wong, C. J., Vandervoort, M., Mikolainis, S., Croitoru, K., Seidman, E., Leddin, D. J., Bitton, A., Drouin, E., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34225 · Cited by 216
Matthes, H., Krummenerl, T., Giensch, M., Wolff, C., & Schulze, J. (2010) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-10-13 · Cited by 207
Kruis, W., Kiudelis, G., Racz, I., Gorelov, I. A., Pokrotnieks, J., Horynski, M., Batovsky, M., Kykal, J., Boehm, S., Greinwald, R., et al. (2009) · Gut · doi:10.1136/gut.2008.154302 · Cited by 204
Garcia Vilela, E., De Lourdes De Abreu Ferrari, M., Oswaldo Da Gama Torres, H., Guerra Pinto, A., Carolina Carneiro Aguirre, A., Paiva Martins, F., Marcos Andrade Goulart, E., & Sales Da Cunha, A. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520801943354 · Cited by 184
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060025 · Cited by 183
Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis
Marshall, J. K., Thabane, M., Steinhart, A. H., Newman, J. R., Anand, A., & Irvine, E. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004115.pub2 · Cited by 182
Defensins and inflammation: The role of defensins in inflammatory bowel disease
Ramasundara, M., Leach, S. T., Lemberg, D. A., & Day, A. S. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05772.x · Cited by 182
Preliminary Study of Ciprofloxacin in Active Crohn's Disease
Arnold, G. L., Beaves, M. R., Pryjdun, V. O., & Mook, W. J. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200201000-00002 · Cited by 181
Methotrexate for maintenance of remission in Crohn's disease
Patel, V., Wang, Y., MacDonald, J. K., McDonald, J. W., & Chande, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006884.pub3 · Cited by 180
Reinisch, W., Angelberger, S., Petritsch, W., Shonova, O., Lukas, M., Bar-Meir, S., Teml, A., Schaeffeler, E., Schwab, M., Dilger, K., et al. (2010) · Gut · doi:10.1136/gut.2009.194159 · Cited by 172
Mantzaris, G. J., Hatzis, A., Kontogiannis, P., & Triadaphyllou, G. (1994) · PubMed · Cited by 171
Gastrointestinal and liver adverse effects of drugs used for treating IBD
Rogler, G. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.10.011 · Cited by 170
Sandborn, W. J., Regula, J., Feagan, B. G., Belousova, E., Jojic, N., Lukas, M., Yacyshyn, B., Krzeski, P., Yeh, C., Messer, C. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.069 · Cited by 169
Combination Ciprofloxacin and Metronidazole for Active Crohn’s Disease
Greenbloom, S. L., Steinhart, A. H., & Greenberg, G. R. (1998) · Canadian Journal of Gastroenterology · doi:10.1155/1998/349460 · Cited by 169
KOHN, A., DAPERNO, M., ARMUZZI, A., CAPPELLO, M., BIANCONE, L., ORLANDO, A., VISCIDO, A., ANNESE, V., RIEGLER, G., MEUCCI, G., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03415.x · Cited by 168
Treton, X., Bouhnik, Y., Mary, J., Colombel, J., Duclos, B., Soule, J., Lerebours, E., Cosnes, J., & Lemann, M. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.028 · Cited by 168
The efficacy of tobramycin in the treatment of ulcerative colitis
BURKE, D. A., AXON, A. T. R., CLAYDEN, S. A., DIXON, M. F., JOHNSTON, D., & LACEY, R. W. (1990) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.1990.tb00456.x · Cited by 166
Riquelme, A. J., Calvo, M. A., Guzmán, A. M., Depix, M. S., García, P., Pérez, C., Arrese, M., & Labarca, J. A. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200301000-00013 · Cited by 166
Hanauer, S. B., Sandborn, W. J., Dallaire, C., Archambault, A., Yacyshyn, B., Yeh, C., & Smith-Hall, N. (2007) · Canadian Journal of Gastroenterology · doi:10.1155/2007/862917 · Cited by 164
Review article: anti‐inflammatory mechanisms of action of Saccharomyces boulardii
POTHOULAKIS, C. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04102.x · Cited by 164
PRANTERA, C., LOCHS, H., CAMPIERI, M., SCRIBANO, M. L., STURNIOLO, G. C., CASTIGLIONE, F., & COTTONE, M. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02879.x · Cited by 163
Cheng, J., Shah, Y. M., Ma, X., Pang, X., Tanaka, T., Kodama, T., Krausz, K. W., & Gonzalez, F. J. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170225 · Cited by 163
Oral budesonide in the treatment of chronic refractory pouchitis
Gionchetti, P., Rizzello, F., Poggioli, G., Pierangeli, F., Laureti, S., MORSELLI, C., Tambasco, R., Calabrese, C., & Campieri, M. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03306.x · Cited by 150
Gionchetti, P., Rizzello, F., Ferrieri, A., Venturi, A., Brignola, C., Ferretti, M., Peruzzo, S., Miglioli, M., & Campieri, M. (1999) · Digestive Diseases and Sciences · doi:10.1023/a:1026648812439 · Cited by 150
Metronidazole in Crohn's Disease
Blichfeldt, P., Blomhoff, J. P., Myhre, E., & Gjone., E. (1978) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365527809179816 · Cited by 148
Fellermann, K., Wehkamp, J., Herrlinger, K. R., & Stange, E. F. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200306000-00008 · Cited by 148
Potential role of Th17 cells in the pathogenesis ofinflammatory bowel disease
Liu, Z., Yadav, P. K., Su, J., Wang, J.-S., & Fei, K. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5784 · Cited by 146
Sandborn, W. J., Korzenik, J. R., Lashner, B. A., Leighton, J. A., Mahadevan, U., Marion, J. F., Safdi, M. A., Sninsky, C. A., Patel, R. M., Friedenberg, K., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.054 · Cited by 144
Assche, G. V., Sandborn, W. J., Feagan, B. G., Salzberg, B. A., Silvers, D., Monroe, P. S., Pandak, W. M., Anderson, F., Valentine, J. F., Wild, G., et al. (2006) · Gut · doi:10.1136/gut.2005.089854 · Cited by 143
Plevy, S. E., Salzberg, B. A., Assche, G. V., Regueiro, M. D., Hommes, D. W., Sandborn, W. J., Hanauer, S. B., Targan, S. R., Mayer, L., Mahadevan, U., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.035 · Cited by 143
Ohkusa, T., Kato, K., Terao, S., Chiba, T., Mabe, K., Murakami, K., Mizokami, Y., Sugiyama, T., Yanaka, A., Takeuchi, Y., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.84 · Cited by 138
Schirbel, A., & Fiocchi, C. (2010) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2010.00449.x · Cited by 138
Holubar, S. D., Cima, R. R., Sandborn, W. J., & Pardi, D. S. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001176.pub2 · Cited by 135
Mesalazine in Inflammatory Bowel Disease: A Trendy Topic Once Again?
Iacucci, M., de Silva, S., & Ghosh, S. K. (2009) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2010/586092 · Cited by 134
Ansari, A. R., Patel, N., Sanderson, J. D., O’Donohue, J., Duley, J. A., & Florin, T. H. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04221.x · Cited by 134
Sakuraba, A., Motoya, S., Watanabe, K., Nishishita, M., Kanke, K., Matsui, T., Suzuki, Y., Oshima, T., Kunisaki, R., Matsumoto, T., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.453 · Cited by 128
Cassinotti, A., Actis, G. C., Duca, P., Massari, A., Colombo, E. M., Gai, E., Annese, V., D'Albasio, G., Manes, G., Travis, S. P. L., et al. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.410 · Cited by 125
Budesonide induction and maintenance therapy for Crohnʼs disease during pregnancy
Beaulieu, D. B., Ananthakrishnan, A. N., Issa, M., Rosenbaum, L., Skaros, S., Newcomer, J. R., Kuhlmann, R. S., Otterson, M. F., Emmons, J. E., Knox, J. F., et al. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20640 · Cited by 119
Isaacs, K. L., Sandler, R. S., Abreu, M. T., Picco, M. F., Hanauer, S. B., Bickston, S. J., Present, D. H., Farraye, F. A., Wolf, D. C., & Sandborn, W. J. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20187 · Cited by 118
Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitis
YAMAMOTO, S., Nakase, H., MIKAMI, S., Inoue, S., Yoshino, T., Takeda, Y., Kasahara, K., UENO, S., Uza, N., Kitamura, H., et al. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03764.x · Cited by 115
Sands, B. E., Jacobson, E. W., Sylwestrowicz, T., Younes, Z., Dryden, G., Fedorak, R., & Greenbloom, S. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21159 · Cited by 114
Feller, M., Huwiler, K., Schoepfer, A. M., Shang, A., Furrer, H., & Egger, M. (2010) · Clinical Infectious Diseases · doi:10.1086/649923 · Cited by 113
Review: Anti-adhesion molecule therapy for inflammatory bowel disease
Ghosh, S. K., & Panaccione, R. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10373176 · Cited by 112
Krishnan, K., Arnone, B., & Buchman, A. L. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21316 · Cited by 111
MELMED, G. Y. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20943 · Cited by 111
Theis, V., & Rhodes, J. M. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03553.x · Cited by 108
Antibiotic therapy for treatment in relapse of intestinal Crohn's disease
Ambrose, N. S., Allan, R. N., Keighley, M. R. B., Burdon, D. W., Youngs, D. J., Barnes, P., & Lennard‐Jones, J. E. (1985) · Diseases of the Colon & Rectum · doi:10.1007/bf02552649 · Cited by 107
A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis.
Mantzaris, G. J., Archavlis, E., Christoforidis, P., Kourtessas, D., Amberiadis, P., Florakis, N., Petraki, K., Spiliadi, C., & Triantafyllou, G. (1997) · PubMed · Cited by 106
Haller, D., Antoine, J., Bengmark, S., Enck, P., Rijkers, G. T., & Lenoir‐Wijnkoop, I. (2010) · Journal of Nutrition · doi:10.3945/jn.109.113746 · Cited by 106
Creed, T., Probert, C. S., Norman, M., Moorghen, M., Shepherd, N. A., Hearing, S. D., Dayan, C. M., & THE BASBUC INVESTIGATORS (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02904.x · Cited by 101
Taxonera, C., Estellés, J., Fernández-Blanco, I., Merino, O., Marín‐Jiménez, I., Acosta, M. B., Saro, C. M., García-Sánchez, V., Gento, E., Bastida, G., et al. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04531.x · Cited by 100
Aminosalicylates for induction of remission or response in Crohn's disease
Lim, W. C., & Hanauer, S. B. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008870 · Cited by 95
Korzenik, J. R., & Dieckgraefe, B. K. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02287.x · Cited by 94
Hanai, H., Takeda, Y., Eberhardson, M., Gruber, R., Saniabadi, A. R., Winqvist, O., & Löfberg, R. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04279.x · Cited by 94
Antiadhesion Molecule Therapy in Inflammatory Bowel Disease
Assche, G. V., & Rutgeerts, P. J. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200207000-00009 · Cited by 92
Peyrin‐Biroulet, L. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i16.2328 · Cited by 92
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate Ulcerative Colitis
Kamm, M. A., Lichtenstein, G. R., Sandborn, W. J., Schreiber, S., Lees, K., Barrett, K., & Joseph, R. E. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20580 · Cited by 90
Randomized clinical trial of metronidazole ointment versus placebo in perianal Crohn's disease
Maeda, Y., Ng, S. C., Durdey, P., et al. (2010) · British journal of surgery · doi:10.1002/bjs.7121 · Cited by 88
Future biologic targets for IBD: potentials and pitfalls
Melmed, G., & Targan, S. R. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.218 · Cited by 82
Ruggiero, C., Lattanzio, F., Lauretani, F., et al. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789909746 · Cited by 80
Use of atorvastatin as an anti‐inflammatory treatment in Crohn's disease
Grip, O., Janciauskiene, S. M., & Bredberg, A. C. A. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.369 · Cited by 78
Brogden, R. N., & Sorkin, E. M. (1989) · Drugs · doi:10.2165/00003495-198938040-00003 · Cited by 78
Rectal tacrolimus in the treatment of resistant ulcerative proctitis
Lawrance, I. C., & Copeland, T. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03841.x · Cited by 77
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis
Baumgart, D. C., MacDonald, J. K., & Feagan, B. G. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007216 · Cited by 76
Toedter, G. P., BLANK, M. A., Lang, Y., Chen, D., Sandborn, W. J., & de Villiers, W. J. S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.454 · Cited by 74
Recombinant human interleukin 10 for induction of remission in Crohn's disease
Buruiana, F. E., Solà, I., & Alonso‐Coello, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005109.pub3 · Cited by 73
Cyclosporine is Safe and Effective in Patients With Severe Ulcerative Colitis
Cheifetz, A. S., Stern, J., Garud, S. S., Goldstein, E. S., Malter, L. B., Moss, A. C., & Present, D. H. (2010) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e3181e883dd · Cited by 71
Leukocyte adhesion molecules in animal models of inflammatory bowel disease
Rivera–Nieves, J., Gorfu, G., & Ley, K. F. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20501 · Cited by 69
An open-label evaluation of rifaximin in the treatment of active Crohn's disease
Shafran, I., & Johnson, L. K. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x53252 · Cited by 68
Helminthic Therapy: Using Worms to Treat Immune-Mediated Disease
Elliott, D. E., & Weinstock, J. V. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1601-3_12 · Cited by 66
The immunology of inflammatory bowel disease
Plevy, S. E. (2002) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(01)00006-1 · Cited by 65
Nguyen, N. H., Zhang, B., Holubar, S. D., Pardi, D. S., & Singh, S. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001176.pub4 · Cited by 62
Valentine, J. F., Fedorak, R. N., Feagan, B. G., Fredlund, P., Schmitt, R., Ni, P., & Humphries, T. J. (2009) · Gut · doi:10.1136/gut.2008.165738 · Cited by 61
Human Defensins in Crohn’s Disease
Wehkamp, J., Fellermann, K., & Stange, E. F. (2005) · KARGER eBooks · doi:10.1159/000086672 · Cited by 60
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis
Liang, H., & Ouyang, Q. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.114 · Cited by 60
Methotrexate for maintenance of remission in Crohn's disease
Patel, V. H., MacDonald, J. K., McDonald, J. W., & Chande, N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006884.pub2 · Cited by 60
Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J., Lyne, A., & JOSEPH, R. E. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03688.x · Cited by 58
Rectal administration of d-alpha tocopherol for active ulcerative colitis: A preliminary report
Mirbagheri, S. A., Nezami, B. G., Assa, S., & Hajimahmoodi, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.5990 · Cited by 52
Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis
Lichtenstein, G. R., BENGTSSON, B., Haptén-White, L., & Rutgeerts, P. J. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03891.x · Cited by 52
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease
Prefontaine, E., MacDonald, J. K., & Sutherland, L. R. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000545.pub2 · Cited by 52
Mucosal Healing and anti TNFs in IBD
Assche, G. V., Vermeire, S., & Rutgeerts, P. (2010) · Current Drug Targets · doi:10.2174/138945010790309902 · Cited by 50
Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis
Chande, N., McDonald, J. W., MacDonald, J. K., & Wang, J. J. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006774.pub3 · Cited by 48
Rossi, C. P., Hanauer, S. B., Tomašević, R., Hunter, J. O., Shafran, I., & Graffner, H. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-22 · Cited by 48
Feagan, B. G., Coteur, G., Tan, S., Keininger, D. L., & Schreiber, S. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.199 · Cited by 47
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn’s disease
Leiper, K., MARTIN, K., Ellis, A., Watson, A. J. M., Morris, A. I., & Rhodes, J. M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03661.x · Cited by 47
T-cell-directed therapies in inflammatory bowel diseases
Monteleone, G., & Caprioli, F. (2010) · Clinical Science · doi:10.1042/cs20100027 · Cited by 46
Pharmacotherapy for induction and maintenance of remission in pouchitis
Sandborn, W. J., McLeod, R. S., & Jewell, D. P. (1998) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001176 · Cited by 45
Rampton, D. S. (2005) · Gut · doi:10.1136/gut.2005.076034 · Cited by 41
Antibiotics Should Be Used as First-line Therapy for Crohnʼs Disease
Greenberg, G. R. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200405000-00021 · Cited by 38
Federico, A., Tuccillo, C., Grossi, E., Abbiati, R. A., Garbagna, N., Romano, M., Tiso, A., Blanco, C. D. V., & Loguercio, C. (2009) · PubMed · Cited by 34
Cyclosporine regulates intestinal epithelial apoptosis via TGF-β-related signaling
Satoh, Y., Ishiguro, Y., Sakuraba, H., Kawaguchi, S., Hiraga, H., Fukuda, S., & Nakane, A. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90608.2008 · Cited by 33
Philpott, J. R., & Miner, P. B. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1627 · Cited by 30
Probiotics for Maintaining Remission of Ulcerative Colitis in Adults
Vi, T., Baird, B. G., & Kockler, D. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m498 · Cited by 28
Uehara, T., Kato, K., Ohkusa, T., Sugitani, M., Ishii, Y., Nemoto, N., & Moriyama, M. (2010) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06231.x · Cited by 26
Certolizumab Pegol: A TNF-α Antagonist for the Treatment of Moderate-to-Severe Crohn's Disease
Smith, L. S., Nelson, M., & Dolder, C. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m314 · Cited by 20
New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
Danese, S., & Angelucci, E. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(09)73157-4 · Cited by 19
Treatment of fulminant ulcerative colitis with cyclosporine A
Holme, Ø., Thiis‐Evensen, E., & Vatn, M. H. (2009) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365520903222673 · Cited by 15
Ornidazole in the treatment of active Crohn's disease.
Jk, T., Manoussakis, C. A., & Papavasiliou, E. (1988) · PubMed · Cited by 11
Cited by
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771
Peter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386
Fucoidan Extracts Ameliorate Acute Colitis
Lean, Q. Y., Eri, R. D., Fitton, J. H., Patel, R. P., & Gueven, N. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128453 · Cited by 142
Natural Withanolides in the Treatment of Chronic Diseases
White, P. T., Subramanian, C., Motiwala, H. F., & Cohen, M. S. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-41334-1_14 · Cited by 139
Metadata
- Authors
- Triantafillidis, J.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2011-04
- Volume
- 5
- Pages
- 185
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2026679422
- Cited by
- 289
- References
- 150
- FWCI
- 11.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.